The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Under the new initiative, each company takes on a defined role across the recycling chain
Subscribe To Our Newsletter & Stay Updated
